Immunopharmacology and Immunotoxicology

期刊简介：The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

【译文】免疫药理学与免疫毒理学期刊致力于针对免疫系统的药物发现和开发，包括小分子药物和生物制剂对免疫细胞和免疫反应的免疫调节作用以及外来物质和药物的免疫毒性。只有描述特定化合物（非提取物）机制的科研才会受到期刊的青睐。期刊将优先考虑针对慢性炎症、过敏、自身免疫、癌症等疾病的免疫疗法的前临床和临床研究。针对中枢免疫靶点的微小药物、疫苗和生物制剂以及基于细胞的治疗（包括树突状细胞疗法、T细胞过继转移和干细胞疗法）也是特别感兴趣的话题。欢迎发表关于免疫系统内潜在新药物靶点或免疫药理学药物开发新技术的文章。该期刊重点关注药物开发、免疫治疗和毒理学，将涵盖感染、过敏、炎症、肿瘤免疫学、退行性疾病、免疫缺陷、神经学、动脉粥样硬化等领域。免疫药理学与免疫毒理学将接受原创稿件、简报、评论、迷你综述、综述、临床试验和临床案例，前提是报告的结果是基于原创、临床或基础研究，且未在任何语言（除与科学会议和研讨会交流的论文的摘要形式外）的任何期刊上发表过。